Prognostic Role of MicroRNA-210 in Various Carcinomas: A Systematic Review and Meta-Analysis

Table 2

Meta-analyses of miR-210 expression to predict the survival outcome.

	Survival outcome	Study 𝑛.	Patient 𝑛.	Model	HR (95% CI)	𝑃 value	Heterogeneity (𝐼^2, 𝑃)	Conclusion
miR-210 total	RFS/DFS	7	699	Random	2.47 [1.36, 4.46]	0.003	62%, 0.01	Positive
	OS	3	314	Fixed	3.44 [1.95, 6.06]	<0.0001	0%, 0.96	Positive
	MFS/DRFS	3	624	Fixed	2.85 [1.76, 4.62]	<0.0001	0%, 0.96	Positive
	DSS	2	134	Fixed	2.68 [1.58, 4.54]	0.0003	0%, 0.67	Positive
miR-210 breast cancer	RFS/DFS	4	542	Fixed	3.36 [2.30, 4.93]	<0.00001	0%, 0.86	Positive
	OS	2	268	Fixed	3.29 [1.65, 6.58]	0.0008	0%, 0.84	Positive
	MFS/DRFS	3	624	Fixed	2.85 [1.76, 4.62]	<0.0001	0%, 0.96	Positive
miR-210 head and neck cancer	RFS/DFS	1	46	Fixed	4.89 [1.71, 13.93]	0.003	—	Positive
	OS	1	46	Fixed	3.77 [1.41, 10.03]	0.008	—	Positive
miR-210 soft-tissue sarcoma	DSS	1	78	Fixed	3.19 [1.22, 8.33]	0.02	—	Positive
miR-210 pancreatic cancer	DSS	1	56	Fixed	2.48 [1.32, 4.68]	0.005	—	Positive
miR-210 renal cell carcinoma	RFS/DFS	2	111	Fixed	0.50 [0.19, 1.30]	0.16	0%, 0.45	Negative